EpimAb Biotherapeutics, Inc., is a China based start-up company founded February 2015 that provides a novel bispecific antibody (bsAb) platform. The company raised over $100M from an international consortium of investors. The company is developing a portfolio of bispecific antibodies based on its proprietary platform FIT-Ig. EpimAb’s lead candidate, EMB-01, is a bsAb binding to cMet and EGFR and is currently being investigated in a global Phase I/II clinical trial. It triggers a novel mechanism of action called co-degradation. Further candidates in later preclinical development are EMB-02, a PD-1/LAG3 bsAb, and EMB-06, a BCMA/CD3 bsAb, both scheduled for IND-filing in 2020. The company also has multiple bsAbs in discovery and lead identification programs with novel mechanisms of action. EpimAb has concluded several partnerships accross the world to explore the potential of FIT-Ig and its FIT-Ig assets in collaborations.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):